Hsbc Holdings PLC Purchases New Shares in BioMarin Pharmaceutical Inc. $BMRN

Hsbc Holdings PLC acquired a new stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 307,543 shares of the biotechnology company’s stock, valued at approximately $17,640,000. Hsbc Holdings PLC owned approximately 0.16% of BioMarin Pharmaceutical as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also modified their holdings of the company. Activest Wealth Management acquired a new stake in shares of BioMarin Pharmaceutical during the 4th quarter valued at about $26,000. CIBC Private Wealth Group LLC boosted its position in BioMarin Pharmaceutical by 38.2% during the fourth quarter. CIBC Private Wealth Group LLC now owns 648 shares of the biotechnology company’s stock worth $39,000 after purchasing an additional 179 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in BioMarin Pharmaceutical in the second quarter valued at approximately $39,000. Caitong International Asset Management Co. Ltd acquired a new stake in BioMarin Pharmaceutical in the third quarter valued at approximately $40,000. Finally, Parallel Advisors LLC increased its position in shares of BioMarin Pharmaceutical by 62.2% in the third quarter. Parallel Advisors LLC now owns 769 shares of the biotechnology company’s stock valued at $42,000 after buying an additional 295 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.

Wall Street Analyst Weigh In

BMRN has been the topic of a number of recent analyst reports. Morgan Stanley increased their target price on BioMarin Pharmaceutical from $119.00 to $124.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. UBS Group set a $88.00 price target on shares of BioMarin Pharmaceutical in a report on Wednesday. Oppenheimer increased their price objective on shares of BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, August 7th. Sanford C. Bernstein dropped their target price on shares of BioMarin Pharmaceutical from $94.00 to $82.00 and set an “outperform” rating on the stock in a research report on Tuesday, May 5th. Finally, Weiss Ratings cut shares of BioMarin Pharmaceutical from a “hold (c-)” rating to a “sell (d)” rating in a research note on Tuesday, August 11th. Two analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $88.79.

BioMarin Pharmaceutical Stock Down 0.5%

NASDAQ BMRN opened at $65.29 on Friday. The business has a fifty day moving average price of $61.50 and a 200 day moving average price of $58.10. BioMarin Pharmaceutical Inc. has a one year low of $49.26 and a one year high of $70.98. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.32 and a current ratio of 2.39. The company has a market cap of $12.64 billion, a P/E ratio of 176.46, a P/E/G ratio of 0.47 and a beta of 0.24.

BioMarin Pharmaceutical (NASDAQ:BMRN) last announced its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a net margin of 2.14% and a return on equity of 5.32%. The company had revenue of $989.71 million for the quarter, compared to analysts’ expectations of $932.03 million. During the same quarter in the previous year, the company posted $1.44 EPS. The firm’s quarterly revenue was up 20.0% on a year-over-year basis. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Research analysts anticipate that BioMarin Pharmaceutical Inc. will post 4.1 EPS for the current fiscal year.

BioMarin Pharmaceutical Profile

BioMarin Pharmaceutical Inc is a biopharmaceutical company specializing in the development and commercialization of therapies for rare genetic and metabolic diseases. The company focuses on addressing unmet medical needs by leveraging enzyme replacement therapy, small molecule pharmacological chaperones and gene therapy technologies. Headquartered in Novato, California, BioMarin operates research and development facilities in the United States and Europe.

The company’s commercial portfolio includes several approved therapies targeting inherited disorders.